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84 Poster Session-Ithat the continued presence of CD4 T cells after HSCT is required
for the development of CD8memory. Upon investigating the mech-
anism(s) of memory loss, we observed an accelerated contraction of
tumor-reactive CD8 cells in the CD4-depleted mice. This acceler-
ated loss of tumor-reactive CD8 cells correlated with increased per-
centages of annexin-V1 pre-apoptotic CD8 cells during the
contraction phase (day 21 after HSCT). A significant proportion
of the annexin-V1 CD8 cells co-expressed programmed death re-
ceptor-1 (PD-1), had an effector phenotype (CD62L-CD441),
and expressed diminished levels of the receptors for IL-7 and IL-
15. These data suggest that PD-1/PD-L1 interactions may play
a role in the loss of CD8 memory. Together, these results show
that CD41 cells can both promote and inhibit anti-tumor responses.
These observations should help us design immunotherapeutic
approaches that can generate ‘‘optimal’’ acute anti-tumor reactivity
after HSCT with development of long-term immunity.230
LONG-TERM FOLLOW-UP OF METASTATIC RENAL CANCER PATIENTS
UNDERGOING REDUCED-INTENSITY ALLOGRAFTING
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Stem cell transplantation from aHLA-compatible sibling donor is
an adoptive immunotherapy for cytokine-resistant, metastatic renal
cancer (RCC). However, the recent introduction of several targeted
therapy compounds has reduced the interest in this therapeutic strat-
egy. We have reanalyzed our transplant series with the aim to detect
long-term benefit form allografting. From February 1999 to May
2005, 25 patients with cytokine-refractory RCC received a re-
duced-intensity allograft from an HLA-id sibling donor. Median
age was 53 years; most (24) had clear-cell histology. Median number
of previous treatments was 1 (0–3). Median days from diagnosis to
allograft were 822. All patients received a thiotepa, fludarabine,
and cyclophosphamide conditioning regimen, and a cyclosporine-
based GVHD prophylaxis. Six patients received DLI at escalating
doses for progressing or non-responding disease. One-year-OS
was 48% (95% CI: 28–68), and 3y-OS was 20% (95% CI: 4–36).
At a median observation time of 65 months, 5 patients are alive,
one in CR, one in VGPR, and three with stable disease.We have an-
alyzed the correlation of the following variables with survival: age at
transplant, time from diagnosis to transplant, serum calcium cor-
rected for albumin levels, lactate dehydrogenase (LDH), C-reactive
protein (CRP), haemoglobin level before transplantation, Karnofsky
performance status, number of CD341/kg infused, number of
CD31/kg infused, progressive disease at 190 after transplant, oc-
currence of acute (any grade) or chronic GvHD. At multivariate
analysis, CRP value before transplant, number of CD341 infused
cells and disease status at 190 significantly correlated with survival.
Survival of patients at favourable/intermediate-risk according to the
MSKCC score that underwent allografting was better in comparison
to the survival predicted by historical controls. We conclude that
transplantation is able to induce long-term disease control in
twenty percent of cytokine-refractory RCC patients. It is unknown
if relapse or PD after targeted therapy will be susceptible to
allograft-mediated GVT effect. The place of allografting in the
treatment of metastatic RCC, alone or in combination with targeted
therapies, needs reappraisal.231
LOW MORBIDITY AND MORTALITY IN A PILOT STUDY OF BUSULFAN,
MELPHALAN AND TOPOTECAN AS PREPARATIVE REGIMEN FOLLOWED
BY AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC PATIENTS WITH HIGH RISK SOLID TUMORS (PRELIMINARY
RESULTS)
Bolotin, E., Pawlowska, A., Hitt, D., Andersen, C., Shakhnovitz, M.,
Sato, J., Forman, S., Rosenthal, J. City of Hope, Duarte, CA
Autologous hematopoetic stem cell transplantation (HDT) has
been utilized as consolidative therapy for pediatric patients with
some encouraging improvement in survival. We hypothesize thatby intensifying therapy which poor prognosis patients currently
receive, it is possible to reduce the risk of relapse after HDT and
the morbidity and mortality will be acceptable. Phase I pediatric
studies of topotecan demonstrated activity against solid tumors.
The dose-limiting toxicity of Phase I studies has been hematopoietic
suppression. The use of hematopoietic stem cell support following
a topotecan-containing preparative regimen will allow utilization
of topotecan in combination with established chemotherapeutic
agents. Patients were assigned to receive topotecan at 2 mg/m2
continuous infusion in combination with fixed doses of busulfan
andmelphalan (B-M-T). In this study, the primary outcome variable
is to evaluate the toxicity of combinedHDTwith B-M-T. Secondary
objective is to analyze the engraftment and outcomes.
Results:Thirteen patients age 2–18 year old (median5 5.4) were
treated on B-M-T-protocol. Seven patients were diagnosed with
neuroblastoma (NBL),Wilms tumor (n5 2), PNET (n5 2), -rhab-
domyosarcoma (RBS) and Ewing sarcoma (each n 5 1). Eight pa-
tients were in CR, five in PR. There were no deaths in the first100
day postHDT.There was 1 admission (1day) to ICU for observation
only. Eleven patients developed grade 1–2 and 2 patients grade 3
liver toxicity (transaminitis and bilirubin elevation), all patients de-
veloped grade 2- 3 mucositis, five patients had grade 2 diarrhea,
one patient developed grade 3 respiratory toxicity, 7 patients had
metabolic toxicities grade 1–2. All patients engrafted. Patients
achieved ANC . 500 on day 8–15 (median 12), platelets .25,000
on day 9 -22 (median 16), no RBC transfusions were required after
day7–25, (median 16.2). Overall 1 1⁄2 year survival rate is 87 % (11
out of 13 patients are alive); event free survival is 78%.Three patients
had recurrent disease: 2 patients with PNET (both patients expired)
and 1 pt with NBL (alive).
Conclusions: Analysis of the preliminary data suggests that B-M-
T regimen in the context of HDT was tolerated without unexpected
or severe toxicity and allowed prompt transition to radiation and/or
maintenance therapy. Further studies are needed to document the
survival benefit of consolidation with B-M-T regimen in children
with high risk solid tumors.232
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Despite continuous advances in the treatment of mBcr, some pa-
tients have very poor outcome. Over the last period, we have inves-
tigated allogeneic immunotherapy as a possibility for tumor control
in patients with advanced mBrC. We have treated 31 pts with Allo
SCT in 2 successive clinical trials. All pts (age: 43 (27–57)) under-
went ASCT after the same RIC (Fludarabin (150mg/m2), Busulfan
(8mg/kg) and Thymoglobulin (2,5mg/kg) or TLI (1 Cgy)) from
a HLA-identical sibling (BM: 13%; PBSC: 87%) followed by CSA.
Prior to ASCT a median of 3 lines of treatment (1–7) have been ad-
ministered over a period of 57 months (6–143).15 (48%) pts under-
went autologous SCT at a median time of 15 months (1–99) prior to
ASCT. All pts were measurable and had a median of 2 metastatic
sites (1–4) (liver:72%, bone:50%, lung:22% and brain:11%). At
transplant : 17 (55%), 10 (32%) and 4 (13%) pts had progressive
(PD), stable disease (SD) and partial response (PR) respectively.
All patients engrafted. The cumulative incidences of grade 2–4
aGVHD and cGVHD were 42% (25–59) and 62% (45–79) respec-
tively. Of note, none of the 31 pts died from TRM. Seven patients
achieved an objective response (CR 5 1; PR 5 6) at a median of
60 days (30–150) for a 24 % (9–39) OR cumulative incidence.
Eventually all pts but 3 progressed at a median of 310 days (120–
560) post transplant. Four pts are alive at median of 23 months
(21–30) post transplant for a 2-year overall survival (OS) probabil-
ity of 29% (16–47)). Results are dramatically different in regards to
disease status at time of transplant. While outcome was uniformly
poor for pts with PD (OR 5 0; 2 year OS probability: 6% (1–27)),
Poster Session-I 85patients with SD achieved a 40% (0–80) OR rate (p 5 .02) for
a 50% (19–80) OS probability at 2 years (p 5 .001). Of the 4 pa-
tients in response at time of transplant, 3 increased their response
(PR 5 2; CR 5 1) and 3 were alive after 2 years. This study shows
that RIC-ASCT can be safely performed in BrC pts without
high transplant related mortality. However we show evidences
that pts with highly progressive disease do not benefit from this ap-
proach. In contrast, a high rate of response associated with pro-
longed survival can be achieved in patients with slowly
progressive disease. Better results could perhaps be achieved only
in pts in the initial disease phase when treatment disease resistance
has not occurred.233
INCREASED FREQUENCY AND RESPONSIVENESS OF PSA-SPECIFIC T
CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PROS-
TATE CANCER
Mattsson, J., Okas, M., Ringden, O., Uhlin, M. Clinical Immunology,
Stockholm, Sweden
Therapies for localized prostate cancer include curative surgery
and radiotherapy while treatment of metastatic disease is often in-
sufficient. Therefore, we started to investigate the potential of allo-
geneic SCT as a treatment for non-curable prostate cancer. A
patient underwent allogeneic SCT from his HLA-identical sister
after a non-myeloablative conditioning regimen as treatment for
his metastatic prostate adenocarcinoma. The patient was treated
with donor lymphocyte infusions after SCT due to threatening re-
jection. Frequencies of prostate-specific T cells in the peripheral
blood of the patient, sibling donor and a group of control individ-
uals were determined by flow cytometry using tetrameric and pen-
tameric HLA A2 complexes containing peptides derived from the
prostate specific antigen (PSA). Cytotoxic activity of PSA-
peptide-specific T-cells against peptide-pulsed target cells was
analyzed ex vivo by 51Cr-release assays. Stable clinical and labora-
tory remission lasting for more than 5 years was observed after
SCT. Using HLA containing pentamers with PSA-derived pep-
tides we could detect prostate-specific CD81T cells in this patient
in high frequencies over several months. Furthermore, higher fre-
quencies of PSA-specific T-cells were revealed in the peripheral
blood of the patient and female controls as compared with male
healthy controls. Recently the PSA levels in the patient started to
increase and prostate biopsies showed prostate carcinoma in 3/8 bi-
opsies, Gleason 414, totally 3.5 mm of cancer (of 100 mm totally).
Due to this progression we have initiated a protocol for adoptive
transfer of allogeneic PSA-specific T cells from the patient. We
will, by using pentamers and flourocrome specific beads separate
out PSA specific T cells from the patient. In order to break a possi-
ble tolerance we will keep them in high concentration of IL-2
and the respective peptides in vitro culture over night before injec-
tion back into the patient. Clinical data of this novel therapy will
be presented at the meeting.Our data suggest that allogeneic
SCT led to the generation of a T cell mediated prostate-specific
immunity in the reported patient. The in vitro and ex vivo immuno-
logical monitoring performed indicate an adjuvant anti-tumor
effect of PSA-specific T cells. This report presents a novel
treatment approach involving allogeneic SCT in prostate cancer
patients who do not respond to chemotherapy and/or cannot
undergo prostectomy.STEM CELL BIOLOGY
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COMPLETE LONG-TERM HEMATOPOIETIC ENGRAFTMENT BY LINEAGE-
DEPLETED ALDH CD341 UCB CELLS
Liu, C.1, DeOliveira, D.1, Sempowski, G.D.2, Chao, N.J.1, Chen, B.J.1,
Storms, R.W.1 1Duke University Medical Center, Durham, NC;
2Duke University Medical Center, Durham, NC
In previous work, we fractionated CD341 umbilical cord blood
(UCB) progenitors to purify cells that express high levels of aldehydedehydrogenase (ALDH). The ALDHbr CD341 cells were enriched
with progenitors that engraft NOD/SCID mice in both short-term
(6–8 week) and long-term (.18 week) transplants. In contrast,
ALDHneg CD341 progenitors were not a significant source of
NOD/SCID repopulating cells. These data strongly imply that
transplantable human progenitors express ALDH; however, one
shortcoming for that work remains that human hematopoietic devel-
opment in NOD/SCID mice is limited to the myeloid and B-lym-
phoid lineages. Because the pace of T cell engraftment is a critical
clinical concern, we have adopted the use of the NOD/SCID-
IL2Rgnull mouse xenograft transplant model. In the current study,
20 mice were transplanted with lineage-depleted ALDHbr CD341
progenitors at doses that ranged from 3,000 to 30,000 cells. In con-
trol studies, similar doses of ALDHneg CD341 cells did not provide
long-term engraftment. So that we might characterize the behavior
of individual UCB, each transplant graft was derived from a single
UCB. In addition, each UCB was assayed in multiple different
mice. Twelve of 13 mice that survived until 21 weeks post-transplant
demonstrated multiple-lineage human hematopoietic engraftment.
Human T, B, NK and myeloid cells were detected in the bone mar-
row and spleen. In addition, in 9mice humanT cells were detected in
the thymus. Furthermore, 7 mice had sufficient thymus tissue to
measure T cell Receptor Excision Circles (TREC). By that assay, 3
of those mice demonstrated active human T cell rearrangements.
As anticipated, the level of engraftment to all tissues was cell
dose-dependent. One strength for this xenograft model was that
engraftment could be monitored over time within the peripheral
blood. Human B cells engrafted within 7 weeks post-transplant
and were detected in 17 of 19 mice ($ 5 B cells/mL). At 16 weeks
post-transplant, 15 of 18 mice maintained detectable B cells. In
contrast, human T cells emerged later, beginning at 13 weeks
post-transplant. However, even by 16 weeks post-transplant, T cells
were only detectable in the peripheral blood of 6 of 18 mice ($ 5 T
cells/mL). These studies provided evidence that ALDHbr CD341
cells establish both short- and long-term hematopoiesis in NOD/
SCID-IL2Rgnull mice. The emergence of T cells was the most
stringent test for long-term engraftment.235
HUMAN EMBRYONIC STEM CELLS-DERIVED HEMANGIOBLAST EXPRESS
HLA-ANTIGENS
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The initial differentiation of vascular endothelium and hemato-
poietic cells during embryogenesis occurs in the mesodermal layer
of the yolk sac, yielding structures called blood islands. We hypoth-
esized that under specific conditions this process can be recapitulated
in embryoid body (EB)-derived cell cultures and that such cells will
be able to form colonies of functional cells with dual hematopoietic/
endothelial potential. We used two-step differentiation technology
to obtain the bipotential blast cells from human embryonic stem cells
(hES). This involved short differentiation in our EB system followed
by differentiation in semisolid culture media supplemented with
mixture of cytokines. We have shown that the occurrence of heman-
gioblast (blast colony-forming cells) – BL-CFC during EB differen-
tiation (day 0–6) is transient and peaks on day 3. The emergence of
this event was associated with expression of T (early mesoderm
gene), and was suppressed by the development of endoderm layer.
Similarly, the highest BL-CFC count was associated with dramatic
increase in early hematopoietic/endothelial genes: CD34, CD31
and KDR. The similar pattern of expression of Patch1 and Gli1
genes suggested association with hedgehog (Hh) pathway. BL-
CFC colonies were composed of 30–50 blast cells on day 6. These
cells had homogenous morphology in Wright-Giemsa stain with
a big nucleus containing disorganized chromatin and a narrow rim
of cytoplasm filled with large-size granules. As shown by FACS stain-
ing, they were heterogenous and expressed markers of early hemato-
poietic and endothelial cells (CD31, CD34, VE-cadherin, Flt-1) and
mature differentiated cells (CD45, CD33, CD146). Some of them
expressed fetal and embryonic globin genes as shown RT-PCR.
Moreover, they could be characterized by higher expression of
HLA class I molecules when compared to hES and EB cells.
